Inflammation, NK Cells, Antisense Protein and Exosomes, and Correlation With Immune Response During HIV Infection (INKASE)

University Hospital Center (CHU)

Status: Enrolling

Conditions: HIV Infections

Treatments: Biological: 20 ml blood test

Study type: Interventional

Funder types: Other

Identifiers

NCT05243381

RECHMPL21_0518

Details and patient eligibility

About

More than 90% of HIV-infected patients on antiretroviral therapy have an undetectable viral load. However, approximately 15% of these individuals do not sufficiently restore their TCD4 lymphocytes and have an unfavorable CD4/CD8 ratio despite good adherence and an undetectable viral load. Factors associated with immunovirological discordance include low CD4 cell counts prior to antiretroviral therapy, low CD4/CD8 ratios and positive cytomegalovirus (CMV) serology. These patients are at risk of significant non-AIDS events and mortality.

The anti-sense protein (ASP) is synthesized from the anti-sense strand of HIV-1. A cytotoxic anti-ASP response of CD8 T lymphocytes and anti-ASP antibodies have been demonstrated in infected patients. The conservation of the ASP gene in HIV-1, the virus responsible for the pandemic, suggests that its maintenance confers an advantage to the virus. ASP induces an inflammatory phenotype in surrounding cells. ASP can be externalized by the cell through its interaction with its cellular partner Bat-3. Once externalized in soluble or exosomal form, Bat-3 has the ability to regulate NK cell activity. During HIV infection, NK functions are disrupted, including those related to the expression of the Bat-3 receptor, NKp30.

In patients, the inflammatory phenomenon is strongly associated with chronic HIV-1 infection. The efficacy of antiviral treatments does not allow a complete normalization of either the immune system function or the inflammatory status of the patient. The observed effect of ASP on inflammation raises the question of the involvement of ASP in the maintenance of a chronic inflammatory state in patients under treatment. Increased inflammation has also been associated in HIV-infected patients with elevated plasma exosome levels. In patients undergoing treatment, chronic inflammation remains a major problem and an important source of comorbidities (cardiovascular in particular) and probably contributes to the immunovirological non-response in immunodiscordant HIV-infected patients.

It is hypothesized that ASP bound to its cellular partner Bat-3 in exosomes would disrupt the cytotoxic activity of NK cells, sustain inflammation and have a deleterious effect on immune reconstitution.

Full description

The main objective of the project is to characterize the presence of ex vivo NK cell perturbations in patients living with HIV (PLHIV) with immunovirological discordance, in relation to ASP expression and plasmatic exosomes. The secondary objectives will be to identify new biological parameters to study and to establish mechanistic hypothesis explaining the results obtained during the study.

The study has a pathophysiological aim and is approved by the committee for the protection of individuals. Two groups of patients will be constituted: one group of PLWHIV with immunovirological discordance (20 patients) and the other group of PLWHIV with a good immune reconstitution (40 patients).

Enrollment: 60 estimated patients

Sex: All

Ages: 45+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patiens living with HIV over 45 years old
• At least 2 measurements of CD4+ T-cell and HIV viral load in the last 2 years
• HIV viral load < 50 copies/ml in the past 2 years
• For the immune non-responder patients : CD4+ T-cell count < 350 cells/mm3 on the last two tests
• For the immune responder patients: CD4+ T-cell count > 500 cells/mm3 on the last two tests

Exclusion criteria

• No antiretroviral treatment
• Immunosuppressive treatment
• History of cancer less than 5 years
• Pregnancy
• Breastfeeding mother
• Adult protected by law or patient under guardianship or curatorship
• Failure to obtain written informed consent after a reflection period
• Not be affiliated to a French social security system or a beneficiary of such a system

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

60 participants in 2 patient groups

Immune non-responder patients

Other group

Description:

* HIV viral load \< 50 copies/ml in the past 2 years * CD4+ T-cell count \< 350 cells/mm3 on the last two tests

Treatment:

Biological: 20 ml blood test

Immune responder patients

Other group

Description:

* HIV viral load \< 50 copies/ml in the past 2 years * CD4+ T-cell count \> 500 cells/mm3 on the last two tests

Treatment:

Biological: 20 ml blood test